Journal of Modern OncologyJournal of Modern Oncology1815-14341815-1442LLC Obyedinennaya Redaktsiya34881Research ArticleMaintenance oncohematological patients and new coronavirus infection: experience of the City Clinical Hospital №52BaryakhElena A.<p>Cand. Sci. (Med.)</p>ebaryakh@gmail.comhttps://orcid.org/0000-0001-6880-9269KochnevaOlga L.<p>hematologist</p>ebaryakh@gmail.comhttps://orcid.org/0000-0001-8094-1713MisyurinaElena N.<p>Cand. Sci. (Med.)</p>ebaryakh@gmail.comhttps://orcid.org/0000-0003-2419-4850ZhelnovaEvgenia I.<p>Cand. Sci. (Med.)</p>ebaryakh@gmail.comhttps://orcid.org/0000-0002-0343-9348YatskovKonstantin V.<p>head of department</p>ebaryakh@gmail.comZagrebnevaAlena I.<p>Cand. Sci. (Med.)</p>ebaryakh@gmail.comhttps://orcid.org/0000-0002-3235-1425ZyangirovRushan R.<p>rheumatologist</p>ebaryakh@gmail.comSamsonovaInna V.<p>Cand. Sci. (Med.)</p>ebaryakh@gmail.comhttps://orcid.org/0000-0002-1228-1765PoteshkinaNatalia G.<p>D. Sci. (Med.), Prof.</p>ebaryakh@gmail.comhttps://orcid.org/0000-0001-9803-2139LysenkoMariana A.<p>D. Sci. (Med.), Prof.</p>ebaryakh@gmail.comhttps://orcid.org/0000-0001-6010-7975PoddubnayaIrina V.<p>D. Sci. (Med.), Prof., Acad. RAS</p>ivprectorat@inbox.ruhttps://orcid.org/0000-0002-0995-1801City Clinical Hospital №52Pirogov Russian National Research Medical UniversityRussian Medical Academy of Continuous Professional Education3006202022274783006202030062020Copyright © 2020, Consilium Medicum2020<p><strong>Justification</strong>. Oncological diseases, along with diabetes, hypertension, cardiovascular and chronic obstructive pulmonary diseases, are associated with severe course and worst prognosis of the new coronavirus infection COVID-19. Due to the limited number of the international studies and the lack of the domestic publications on the analysis of the course of COVID-19 in patients with oncohematological pathology and the patient management tactics, this work seems extremely topical.</p>
<p><strong>Materials and methods</strong>. 24.04.202031.05.2020, 110 patients with oncohematological pathology associated with new coronavirus infection were observed on the basis of the hematology service of City Clinical Hospital №52: 59 women and 51 men, mean age 58 (1890) years.</p>
<p><strong>Results</strong>. Currently, 24 (22%) patients among 110 are continuing treatment. The outcome of the disease is observed in 86 (78%) patients: 50 (58%) patients were discharged from hospital with complete or partial resolution of pneumonia, 36 (42%) of the 86 patients died. The groups did not differ in gender. The median age was higher in the group of deceased patients (66 vs. 54 years in patients who had a favorable outcome after COVID-19). The somatic status ECOG 34 was an independent predictive factor determining the adverse outcome of the disease. The third part of the patients from the group with a fatal cases due to a severe condition in the debut of the disease immediately were hospitalized in the intensive care unit (ICU), 2 (6%) of them had died within the first day. Disposition, according to the nosology showed a significant predominance among patients with an adverse outcome associated with acute leukemia (18% vs 39%). Patients with resistant course of hemoblastosis accounted for 50% of deceased patients. Severe form of the course of COVID-19 infection was twice as frequently (46% vs 84%) among patients with an adverse outcome of the disease, that was associated with both the initial more severe group of patients (33% were hospitalized in the ICU), and less curability of pneumonia against the background of the adverse prognostic factors: the older age group, the predominance of patients with acute leukemia and resistant course of oncohematological diseases. Specific anticancer therapy and COVID-19 therapy were comparable in both groups.</p>
<p><strong>Conclusions</strong>. Identification of new coronavirus infection against a backdrop of oncohematological disease is associated with a severe course of COVID-19 and high death rate 42%. According to the preliminary obtained results, the adverse prognostic factors of COVID-19 in patients with oncohematological diseases include: elderly age, the poor somatic status (ECOG 34), relapse or progression of hemoblastosis and nosological affiliation to acute leukemia.</p>new coronavirus infectionCOVID-19non-Hodgkin’s lymphomasacute leukemiahemoblastosisновая коронавирусная инфекцияCOVID-19неходжкинские лимфомыострые лейкозыгемобластозы[Особенности ведения онкогематологических больных в условиях пандемии COVID-19. Под ред. И.В. Поддубной. М.: Экон-Информ, 2020. [Features of management of oncohematological patients in the context of the COVID-19 pandemic. Ed. I.V. Poddubnaia. Moscow: Econ-Inform, 2020 (in Russian).]][Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Минздрав России. Версия 5 (08.04.2020). [Vremennye metodicheskie rekomendatsii. Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19). Minzdrav Rossii. Versiia 5 (08.04.2020) (in Russian).]][Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Минздрав России. Версия 6 (28.04.2020). [Vremennye metodicheskie rekomendatsii. Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19). Minzdrav Rossii. Versiia 6 (28.04.2020) (in Russian).]][Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Минздрав России. Версия 7 (03.06.2020). [Vremennye metodicheskie rekomendatsii. Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19). Minzdrav Rossii. Versiia 7 (03.06.2020) (in Russian).]][Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. www.thelancet.com. 2020. https://doi.org/10.1016/ S0140-6736(20)31180-6][Cao B, Wang Y, Danning Wen D et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 2020; 382: 1787–99.][Kuderer NM, Choueiri TK, Shah DP et al Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 2020; S0140-6736(20)31187-9. DOI: 10.1016/S0140-6736(20)31187-9][Poortmans PM, Guarneri V, Cardoso M-J. Cancer and COVID-19: what do we really know? www.thelancet.com. 2020. https://doi.org/10.1016/ S0140-6736(20)31240-X]